Accupril tablets recalled by Pfizer for nitrosamine impurity
Pfizer is recalling 2,079 bottles of Accupril (Quinapril HCl) 10 mg tablets due to N-nitrosoquinapril exceeding acceptable limits. The affected lot was distributed nationwide and in Puerto Rico.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This FDA Class II recall addresses a manufacturing deviation with an impurity above acceptable limits. No illnesses or injuries have been reported. This is a precautionary recall without reported harm, consistent with Moderate severity.
Plain-English summary
Pfizer Inc. is recalling 2,079 bottles of Accupril (Quinapril HCl Tablets) 10 mg due to a manufacturing deviation. The recalled lot contains N-nitrosoquinapril at levels above what is acceptable according to manufacturing standards.
The affected lot is Lot DR9639 with an expiration date of March 31, 2023 (NDC 0071-0530-23). The product was distributed nationwide and in Puerto Rico.
Patients currently using this medication should consult their healthcare provider or pharmacist before making any changes to their treatment. Consumers with this specific lot should contact Pfizer or their pharmacy for instructions on return or replacement.
The recalled product
- Product
- Accupril (Quinapril HCl Tablets) 10 mg, 90 Tablets Rx only NDC 0071-0530-23 Distributed by: Parke-Davis Division of Pfizer Inc. NY, NY 10017
- Manufacturer
- Pfizer Inc.
- Affected units
- 2,079
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot: DR9639 Exp. MAR 31 2023
Distribution
Part of a larger recall action
This product is one of 3 recalled by Pfizer Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 3 products in this recall →Related recalls
Same manufacturer · Pfizer Inc.
See all →- HighSodium bicarbonate injection vials recalled for lack of assurance of sterility
FDA (Drugs) · 2025-08-27
- HighEpinephrine injection vials recalled for lack of assurance of sterility
FDA (Drugs) · 2025-08-27
- HighBicillin L-A 2.4 million unit vials recalled after particulates found
FDA (Drugs) · 2025-08-06
- HighBicillin L-A penicillin vials recalled after particulates found during visual inspection
FDA (Drugs) · 2025-08-06
- ModerateDobutamine Injection Recall Due to Discoloration and Cracked Vials
FDA (Drugs) · 2025-07-02
Same hazard · nitrosamine impurity
See all →- HighEnovachem duloxetine capsules exceed the nitrosamine acceptable intake limit
FDA (Drugs) · 2026-06-10
- HighCipla cinacalcet 60 mg tablets exceed the nitrosamine daily intake limit
FDA (Drugs) · 2026-04-22
- HighCipla cinacalcet 30 mg tablets exceed the nitrosamine daily intake limit
FDA (Drugs) · 2026-04-22
- HighCipla cinacalcet 90 mg tablets exceed the nitrosamine daily intake limit
FDA (Drugs) · 2026-04-22
- HighPrazosin hydrochloride 100-count bottles recalled over nitrosamine impurity
FDA (Drugs) · 2026-04-08